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Glucocorticoids (GCs) are frequently used for treating and preventing chronic lung disease and circulatory
dysfunction in premature infants. However, there is growing concern about the detrimental effects of systemic GC
administration on neurodevelopment. The first choice of GCs to minimize the adverse effects on the developing
brain is still under debate. We investigated the effect of commonly used GCs such as dexamethasone (DEX),
betamethasone (BET) and hydrocortisone (HDC) on the proliferation of human-induced pluripotent stem cell
(iPSC)-derived neuronal progenitor cells (NPCs). In this study, NPCs were treated with various concentrations of GCs
and subjected to cell proliferation assays. Furthermore, we quantified the number of microtubule-associated protein
2 (MAP2) positive neurons in NPCs by immunostaining. All GCs promoted NPC proliferation in a dose-dependent
manner. We also confirmed that MAP2-positive neurons in NPCs increased upon GC treatment. However, differential
effects of GCs on MAP2 positive neurons were observed when we treated NPCs with H2O2. The total numbers of
NPCs increased upon any GC treatment even under oxidative conditions but the numbers of MAP2 positive neurons
increased only by HDC treatment. GCs promoted human iPSCs–derived NPC proliferation and the differential effects of
GCs became apparent under oxidative stress. Our results may support HDC as the preferred choice over DEX and BET
to prevent adverse effects on the developing human brain.
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In recent years, systemic glucocorticoids (GCs) have fre-
quently been administered to treat and prevent chronic
lung disease (CLD), which is also known as bronchopul-
monary dysplasia, and circulatory dysfunction in prema-
ture infants. GCs administration dramatically improves
the outcome of premature infants with established CLD
(Halliday et al. 2009, 2010). However, the use of GCs, es-
pecially dexamethasone (DEX), for CLD patients is re-
ported to show detrimental effects on the developing
brain with subsequent behavioral alterations and cerebral
palsy (Murphy et al. 2001; Shinwell et al. 2000; Yeh et al.
2004). Betamethasone (BET) is also reported to impair
cerebral blood flow velocities in very premature infants* Correspondence: shintaku@med.osaka-cu.ac.jp
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in any medium, provided the original work is pwith severe CLD (Cambonie et al. 2008). A few studies
have suggested that patients treated with HDC showed no
neurological adverse effect (Benders et al. 2009; de Jong
et al. 2011; Watterberg et al. 2007), but another study
showed that GCs reduced proliferation and induce differ-
entiation of neurons (Aden et al. 2011). The effect of GCs
on the developing human brain remains elusive, and ran-
domized clinical trials are required in order to establish
better neurological outcomes.
Many studies have been conducted to reveal the mecha-
nisms underlying the adverse effects of GCs. DEX treat-
ment has been shown to decrease brain weight (Kanagawa
et al. 2006) and inhibit hippocampal neurogenesis (Kim
et al. 2004) in rats. In addition, DEX inhibited the prolifer-
ation of embryonic rat neural stem cells (Bose et al. 2010).
Duksal et al. (2009) reported that high dose DEX caused
brain weight loss due to neuronal apoptosis. Although
many animal studies have indicated that GCs suppress theis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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GCs affect neuronal cells in humans.
In the present study, we investigated the effects of
commonly used GCs such as DEX, BET and HDC on
the proliferation of human iPS cell-derived NPCs, which
were used as a model of human embryonic and neonatal
NPCs. We further focused on the subpopulation of
NPCs that were committed to the neuronal lineage. The
effects of GCs on neural cell proliferation were evalu-
ated. We also examined whether oxidative stress affected
the sensitivity of NPCs to GCs.
Methods
Reagents
DECADRON® (Dexamethasone) was obtained from MSD
(Tokyo, Japan). Rinderon® (Betamethasone) was from
Shionogi & Co., Ltd. (Osaka, Japan). Hydrocortone® (hydro-
cortisone) was from Nichi-Iko Pharmaceutical Co., Ltd.
(Toyama, Japan). Hydrogen peroxide solution (H2O2) was
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
Human iPS cell culture and neural progenitor cells induction
The study was approved by the Ethics Committees of the
Osaka City University (approval #2472) and was conducted
according to the declaration of Helsinki. In this study, we
used human iPSCs derived from fetal lung fibroblast
(MRC-5) cells and the iPSCs were maintained by standard
culture methods as described previously (Saito et al. 2011).
Neural induction was performed as described previously
(Chambers et al. 2009). Briefly, neural induction will be ini-
tiated by 10 μM SB431542 (TGF-β inhibitor, Wako) and
200 ng/ml of Noggin (R&D Systems, Minneapolis, MN).
After 8 days of neural induction, cells are dissociated with
accutase (Chemicon, Temecula, CA) and plated onto poly-
ornithine and laminin (Sigma, St. Louis, MO) with neuro-
basal medium supplemented with 2% B27 (Invitrogen),
20 ng/ml bFGF (Wako), 20 ng/ml epidermal growth factor
(EGF, Invitrogen). Rosette neural stem cells (R-NSC) will
form within a few days. R-NSCs were enriched by Neural
Rosette Selection Reagent® (Stem Cell Technologies, Toronto,
Canada). NPCs were obtained after a few passages and
subjected to proliferation assays. Schematic diagram of in-
duction of NPCs and representative growth rate of NPCs
are shown in Additional file 1: Figure S1.
Proliferation assay
Cell proliferation was measured using Cell Titer 96
AQueous One Solution cell proliferation assay according
to the manufacturer’s protocol (Promega, Madison, WI).
Ninety-six-well tissue culture plates were coated with
poly-ornithine and laminin. NPCs were plated at a dens-
ity of 6 × 103 cells per well. GCs treatment was started
48 h after plating. After 4 days of GCs exposure, prolif-
eration assays was performed by adding Cell Titer 96AQueous One Solution and incubating at 37°C for 2 h.
Then absorbance was measured at 450 nm with a micro
plate reader (MTP-300:CORONA ELECTRIC).Immunocytochemistry and MAP2 positive cell count
Chamber slides, μ-slide IV (Ibidi, Martinsried, Germany)
were coated with poly-ornithine and laminin. NPCs were
plated in the chamber slides at a density of 1.8 × 104 cells
per well and cultured for 48 h, followed by exposure to
GCs. After 4 days incubation, cells were subjected for im-
munostaining. Mouse monoclonal anti-MAP2 antibody
(AP20) (Chemicon, Temecula, CA) (1:200), Alexa Fluor®
488 Goat Anti-Mouse IgG (Invitrogen) (1:1000), and 4,6-
diamidino-2-phenylindole (DAPI) (Sigma) were used. For
quantification of MAP2 positive cells and DAPI positive
cells, 5 microscopic fields were randomly selected and
cells were automatically counted using ImageJ (Schneider
et al. 2012). Cell counts per field were standardized against
untreated cell counts for each experiment.Statistical analysis
For statistical analysis, data were evaluated by analysis of
variance (Statcel3, add-in software to Microsoft® Excel
2007). Differences between groups were analyzed by
single-factor ANOVA with Tukey-Kramer. Results are
displayed with mean ± SD. P values < 0.05 were consid-
ered statistically significant. All experiments were re-
peated more than three times.Results
GC treatment promoted neural progenitor cell proliferation
To evaluate the effect of GCs on the proliferation of NPCs,
we initially performed a cell proliferation assay. NPCs were
exposed to GCs for 4 days and subjected to a proliferation
assay. As shown in Figure 1a, the average absorbance of the
samples treated with DEX of 5 nM, 500 nM, and 50 μM
were 107.5 ± 10.2 (P value =NS), 113.8 ± 17.1 (P value <
0.05), and 124.0 ± 8.9 (P value < 0.01), respectively. The
samples treated with BET of 5 nM, 500 nM, and 50 μM
were 108.7 ± 9.8 (P value = NS), 110.2 ± 12.4 (P value =
NS), and 114.4 ± 9.4 (P value < 0.01), respectively (Figure 1b).
The samples treated with HDC of 5 nM, 500 nM, and
50 μM were 105.0 ± 8.6 (P value = NS), 114.0 ± 11.3
(P value < 0.01), and 118.4 ± 9.3 (P value < 0.01), respect-
ively (Figure 1c). We also calculated the P values for com-
parison of each GC from 5 nM to 50 μM. Both DEX and
HDC showed statistically significant differences on the
absorbance between 5 nM and 50 μM (P value < 0.01).
In summary, our results indicate that the GCs stimu-
late proliferation of NPCs in a dose-dependent manner.
Moreover, the proliferative effect was independent from
the types of GCs we tested.
Figure 1 Glucocorticoid (GC) treatment promoted NPC
proliferation. Cell proliferation was measured by absorbance using
Cell 96 AQueous One Assay kit. The average absorbance data were
expressed as percentages of untreated samples. P values were
calculated by comparing with untreated samples (n = 3). *P < 0.05,
**P < 0.01. (One-way ANOVA with Tukey-Kramer). The cells were
treated with the indicated concentration of (a) dexamethasone
(DEX), (b) betamethasone (BET), and (c) hydrocortisone (HDC).
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positive neuron
GC treatment is reported to increase apoptosis in dis-
tinct neural regions in the brain. The studies indicate
that neuronal cells are more susceptible than glial cells
(Duksal et al. 2009; Hassan et al. 1996). Since iPS cell-
derived NPCs consist of heterogeneous populations, we
focused on proliferation of the cells that were committed
to the neuronal lineage in the GC-treated NPCs.
Microtubule-associated protein 2 (MAP2) is specific-
ally expressed in vivo in the granular layer in the embryo
(Tucker et al. 1989). We performed immunostaining
using an anti-MAP2 antibody to evaluate the number of
neuronal lineage cells after GC treatments (Figure 2c).
For this experiment, NPCs were exposed to GCs for
4 days and then subjected to analysis.
We compared the MAP2 positive cell count with the
untreated NPCs and calculated the P values. As shown in
Figure 2b, the average numbers of MAP2-positive neurons
treated with DEX of 500 nM and 50 μM were 125.4 ± 36.0
(P value < 0.05) and 158.6 ± 35.3 (P value < 0.01), respect-
ively. The MAP2-positive neurons treated with BET of
500 nM and 50 μM were 122.7 ± 36.0 (P value = NS) and
173.0 ± 39.6 (P value < 0.01), respectively (Figure 2c). The
MAP2-positive neurons treated with HDC of 500 nM and
50 μM were 116.0 ± 26.1 (P value = NS) and 145.1 ± 36.7
(P value < 0.01), respectively (Figure 2d). All GCs showed
statistically significant differences on the average numbers
of MAP2-positive neurons between 5 nM and 50 μM
(DEX and HDC showed P value < 0.05, BET showed
P value < 0.01). These data indicate that the MAP2 posi-
tive cell number significantly increased as the cells were
treated with a higher dose of GCs. Moreover, we found no
significant differences in proliferative potency between
DEX, BET, and HDC.
GC treatment promoted NPC proliferation under
oxidative stress
Involvement of oxidative stress was suggested in the
pathogenesis of neonatal CLD (Ogihara et al. 1999) and
oxidative stress is thought to be a cause of neuronal
damage (Ikonomidou and Kaindl 2011). To mimic clin-
ical situations during the use of GCs, we treated NPCs
with H2O2 for oxidative stress and examined the effect
of GCs on NPC proliferation. We have initially tested
Figure 2 GC treatment promoted cell proliferation of MAP2 positive neurons. (a) Representative pictures of NPCs stained with an antibody
against MAP2 (red) and nuclear counterstain DAPI (blue). Phase, phase contrast image. Scale bar, 100 μm. (b-d). Quantification of MAP2 positive
neurons using ImageJ. P values were calculated by comparing GC treated with untreated samples (n = 3). *P < 0.05, **P < 0.01. (One-way
ANOVA with Tukey-Kramer). The cells were treated with the indicated concentration of (b) dexamethasone (DEX), (c) betamethasone (BET), and
(d) hydrocortisone (HDC).
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GCs. 300 μM H2O2 concentration was reasonably seen
the effect of the stress on cellular proliferation (Additional
file 2: Figure S2).
NPCs were treated with 300 μM H2O2 1 day before
GC treatment. Similarly, we expressed the average ab-
sorbance data as percentages of untreated samples, and
the mean percent ± SD of untreated samples was 100 ±
5.0. The results are shown in Figure 3. The average ab-
sorbance of cells that were treated only with H2O2 was
88.8 ± 7.8, which is significantly reduced relative to the
untreated samples (P value < 0.05, Figure 3).Initially, we compared the average absorbance with
only H2O2 treated NPCs and calculated the P values
(Figure 3). The average absorbance of the samples
treated with DEX of 5 nM, 500 nM, and 50 μM under
H2O2-treated condition were 93.8 ± 10.3 (P value = NS),
96.6 ± 8.0 (P value = NS), and 124.0 ± 6.9 (P value < 0.01),
respectively. The average absorbance of cells treated
with BET of 5 nM, 500 nM, and 50 μM under H2O2-
treated condition were 96.0 ± 8.6 (P value = NS), 103.2 ±
7.6 (P value < 0.01), and 109.4 ± 2.9 (P value < 0.01), re-
spectively. The average absorbance of cells treated with
HDC of 5 nM, 500 nM, and 50 μM under H2O2-treated
Figure 3 GC treatment promoted NPC proliferation under oxidative stress. Cell proliferation was measured by absorbance using Cell 96
AQueous One Assay kit. The average absorbance data were expressed as percentages of untreated samples. P values were calculated by
comparing GC treated with untreated samples (n = 3). *P < 0.05, **P < 0.01. (One-way ANOVA with Tukey-Kramer). DEX: dexamethasone, BET:
betamethasone, HDC: hydrocortisone.
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(P value < 0.01), and 107.2 ± 2.5 (P value < 0.01), respect-
ively. When we compared the average absorbance be-
tween each GC in the same concentration with or
without H2O2, we did not observe statistical significance
except for DEX at 5 nM and 500 nM (P value < 0.01).
These data indicate that the absorbance significantly in-
creased as the cells were treated with a higher dose of
GCs even under H2O2-treated condition.
In summary, our results indicate that GCs stimulated
the proliferation of NPCs under H2O2-treated condi-
tions. All examined GCs induced NPC proliferation in a
dose dependent manner regardless of oxidative stress.
HDC alone promoted cell proliferation of MAP2 positive
neuron under oxidative stress
Neurons are more sensitive to oxidative stress than any
other type of cells in the brain (Hayashi et al. 2012).
Therefore, we examined the effects of the GCs on the
proliferation of MAP2-positive neurons under an oxida-
tive stress condition. NPCs were treated with 300 μM
H2O2 1 day before GC treatment, then NPCs were ex-
posed to GCs for 4 days and subjected to immunostain-
ing using an anti-MAP2 antibody (Figure 4a).
We compared the MAP2 positive cell count with the
condition treated with H2O2 alone (74.9 ± 31.8). The aver-
age numbers of MAP2-positive neurons treated with DEX
of 500 nM and 50 μM were 75.6 ± 52.3 (P value = NS) and
84.7 ± 27.2 (P value = NS), respectively. The average num-
bers of MAP2-positive neurons treated with BET of
500 nM and 50 μM were 93.1 ± 41.1 (P value =NS) and
113.1 ± 47.7 (P value = NS), respectively. The averagenumbers of MAP2-positive neurons treated with HDC of
500 nM and 50 μM were 108.5 ± 34.0 (P value < 0.05) and
143.6 ± 19.4 (P value < 0.01), respectively. Unlike DEX and
BET, HDC significantly increased the number of MAP2-
positive neurons compared with the untreated samples
even under the H2O2-treated condition.
In conclusion, only HDC promoted significant cell
proliferation of MAP2 positive neurons as well as the
total number of NPCs under oxidative stress. DEX and
BET, however, increased the total number of NPCs with-
out increasing MAP2 positive neurons.
Discussion
In this study, we investigated the effect of GCs on prolif-
eration of NPCs derived from human iPS cells. Unex-
pectedly, all GCs we tested induced NPC proliferation in
a dose dependent manner. We also confirmed that
MAP2 positive neuronal cells were increased by GC
treatment. Furthermore, we investigated the proliferative
effects of GCs under an oxidative stress condition that
could be more relevant to the clinical setting. The find-
ings revealed that all GCs stimulated the total number
of NPCs even under the oxidative condition, but MAP2
positive neurons were only increased by HDC treatment.
Our results support the finding that HDC would be the
preferred choice over DEX and BET to prevent adverse
effects on the developing brain.
Cell cycle regulation induced by GCs
Samarasinghe et al. (Samarasinghe et al., 2011) demon-
strated that the binding of GCs to the GC receptor
(GR) decreased gap junction-mediated intercellular
Figure 4 GCs showed different effects on proliferation of the MAP2-positive neurons under H2O2-treated conditions. (a) Representative
pictures of NPCs were stained with an antibody against MAP2 (red) and nuclear counterstain DAPI (blue). The cells were pre-exposed to H2O2
and treated with 50 μM of the indicated GCs. Phase, phase contrast image. Scale bar, 100 μm. (b) Quantification of MAP2 positive neurons
using ImageJ. P values were calculated by comparing GC treated samples with the samples treated with H2O2 alone (n = 3). *P < 0.05, **P < 0.01.
(One-way ANOVA with Tukey-Kramer). DEX: dexamethasone, BET: betamethasone, HDC: hydrocortisone. Note that HDC alone promoted
significant cell proliferation of MAP2 positive neurons under oxidative stress.
Ninomiya et al. SpringerPlus 2014, 3:527 Page 6 of 8
http://www.springerplus.com/content/3/1/527communication and led to a decrease in the rate of cells
in the S phase. They concluded that GC suppresses cell
proliferation through this mechanism. Sundberg et al.
(2006) reported that the activation of GR prevents cyclin
D1-mediated cell cycle progression and that the high dose
GC inhibits proliferation of rat embryonic NPCs. Similar
inhibitory mechanisms of GCs were reported by others
using rodent cells (Bose et al. 2010). Moors et al. (2012)
examined the effect of DEX on neurospheres derived from
a 16-week human aborted fetus and found that DEX
inhibits the proliferation of human NPCs. However, in our
experiment using NPCs derived from human iPS cells, allGCs we tested including DEX intriguingly promoted the
proliferation of NPCs.
Neuroprotective effects of GCs
GCs exhibit protective effects on postmitotic neurons.
Harms et al. (2007) showed that GCs induce phos-
phatidylinositol 3-Akt-kinase-dependent phosphorylation
of p21Waf1/Cip1 and it works as a novel anti-apoptotic
pathway for postmitotic primary cortical neurons isolated
from rats and mice. By in vivo and in vitro studies using
the rat model, Jeanneteau et al. (2008) showed that GCs
activate the Trk neurotrophin receptor and thus exhibit
Ninomiya et al. SpringerPlus 2014, 3:527 Page 7 of 8
http://www.springerplus.com/content/3/1/527neuroprotective effects. In any case, neuroprotective path-
ways in postmitotic neurons prevent new cell cycles.
Therefore, such a neuroprotective mechanism alone can-
not explain how GCs induce NPC proliferation.Differential mechanisms of action between GCs
We demonstrated that GCs differently stimulate the prolif-
eration of MAP2-positive neurons under oxidative stress.
HDC physically associates with both GR and mineralcorti-
coid receptor (MR) in vivo, while DEX and BET physically
associate only with GR but not with MR (De Kloet et al.
1998). As described above, it has been reported that GR
suppresses cell proliferation and causes apoptosis. In the
present study, the GCs showed similar effects under non-
stressed conditions. Under oxidative stress conditions,
however, HDC alone increased the number of MAP2 posi-
tive neurons. This may suggest that the activation of MR
plays an important role in the proliferation of neurons
under oxidative stress. Another possibility could be the dif-
ference in the inactivation mechanisms of the GCs. While
HDC is metabolized by 11βHSD2, DEX and BET are not
sensitive to inactivation by 11βHSD2 (Heine and Rowitch
2009; Noguchi et al. 2011). Thus, the continuous GR activ-
ity may induce apoptosis under stress conditions. The hu-
man NPCs used in this study were indeed expressing both
MR and GR (Additional file 3: Figure S3).Clinical implications
Our current study demonstrates that NPCs proliferate in
response to GCs but MAP2 positive neurons are sensitive
to oxidative stress. It is interesting that the response to
HDC is less affected by oxidative stress than DEX or BET
(Figure 4). Halliday et al. (2009, 2010) recommended
avoiding frequent use of GCs for CLD treatment but there
is insufficient evidence regarding which types of GCs to
use in order to minimize adverse neurological outcomes.
Further clinical and mechanistic studies are required to de-
termine the optimal choice of GCs for children with CLD.
In conclusion, we evaluated the effect of GCs on NPC
derived human iPS cells and found unique proliferative
effects on NPCs, which were altered by external stress.
Further mechanistic studies are needed to reveal how
GCs induce NPC proliferation and how oxidative stress
modulates the effects of GCs.Additional files
Additional file 1: Figure S1. Derivation of neural progenitor cells
(NPCs) from human iPS cells. (a) Schematic diagram of induction of NPCs.
R-NSC: Rosette neural stem cells. (b) Representative picture of R-NSC
and NPCs in phase contrast image. R-NSC stained positive for Nestin
(green/insert). Bar:100 μm. (c) Growth curve for NPCs. Cell number was
automatically measured by using IncuCyte imaging system (Essen
BioScience, K.K., Japan).Additional file 2: Figure S2. Effect of H2O2 treatment on NPC proliferation
under oxidative stress. NPCs were treated various concentration of H2O2
as indicated. Cell proliferation was measured by absorbance using Cell
96 AQueous One Assay kit. The average absorbance data were
expressed as percentages of untreated samples.
Additional file 3: Figure S3. Expression of glucocorticoid receptor and
mineral corticoid receptor in NPCs Quantitative RT-PCR analysis was
performed on MRC5-iPSC and NPCs. The mRNA values were expressed
relative to the control gene (β-actin). GR: glucocorticoid receptor, MR:
mineral corticoid receptor.
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